Facial Injectables Market Is Projected to Be Worth US $5.8 Bn by 2024
The North America facial injectables market features a largely monopolistic landscape with only one company holding dominating share. Transparency Market Research (TMR) notes that Allergan Plc. accounts for a lion's share of 62.0% in the market. The dominant stronghold the company has in the market derives its strength from its robust brand value of its facial injectable offering such as Juvederm and Botox (Botulinum toxin). The Botox is anticipated to witness leading demand presently and is likely to hold its...
View full press release